澳大利亚的莱沃多巴使用:对制药福利计划10%数据的分析
Andrew Evans1, Benjamin J Waterhouse2
1The Royal Melbourne Hospital, Parkville, Victoria, Australia.
BMJ neurology open
|January 25, 2024
概括
在澳大利亚,许多帕金森病患者在补充治疗前接受高剂量利沃多巴. 这表明,许多人可能会从早期的附加治疗中受益,以管理运动波动和运动障碍.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 利沃多巴是帕金森病的主要治疗方法.
- 运动波动和Levodopa诱导的运动障碍需要额外的治疗.
- 关于在澳大利亚启动附加治疗的最佳利沃多巴剂量存在缺乏共识.
研究的目的:
- 为了调查澳大利亚帕金森病的治疗模式.
- 在第一个补充治疗开始时,专注于levodopa剂量.
主要方法:
- 使用澳大利亚制药福利计划 (PBS) 数据的回顾性观察性研究 (10%的样本).
- 包括的患者在12个月内 (2007-2021) 至少发放了三个PBS补偿的Levodopa处方.
- 提取了关于处方,处方者类型和物品代码的数据.
主要成果:
- 包括154,850名患者;42,330人 (27%) 开始补充治疗.
- 在添加前的勒沃多巴剂量从每天100毫克到每天1000毫克不等.
- 神经科医生最常开的补充疗法;~40%的患者在补充前接受了600毫克/天以上的利沃多巴剂量.
结论:
- 澳大利亚帕金森病患者中有很大一部分正在接受高剂量利沃多巴单疗法.
- 许多患者可能会从早期引入附加疗法中受益.
- 当前的治疗模式可能与最佳的症状管理策略不一致.
关键词:
帕金森病是帕金森病的一种.相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
138
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
138
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
Analysis of Population Pharmacokinetic Data
257
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
257


